98.95
5.22 (5.57%)
| Penutupan Terdahulu | 93.73 |
| Buka | 96.06 |
| Jumlah Dagangan | 2,776,363 |
| Purata Dagangan (3B) | 1,410,011 |
| Modal Pasaran | 8,592,942,080 |
| Harga / Jualan (P/S) | 650.22 |
| Harga / Buku (P/B) | 16.65 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2026 |
| EPS Cair (TTM) | -3.06 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.06% |
| Nisbah Semasa (MRQ) | 8.06 |
| Aliran Tunai Operasi (OCF TTM) | -169.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -68.57 M |
| Pulangan Atas Aset (ROA TTM) | -25.34% |
| Pulangan Atas Ekuiti (ROE TTM) | -65.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Spyre Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.63 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.71% |
| % Dimiliki oleh Institusi | 106.07% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Fairmount Funds Management Llc | 31 Mar 2026 | 4,018,101 |
| Paradigm Biocapital Advisors Lp | 31 Mar 2026 | 1,957,266 |
| Commodore Capital Lp | 31 Mar 2026 | 1,912,380 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BURROWS SCOTT L | - | 88.89 | -7,500 | -666,675 |
| SLOAN SHELDON | - | 88.89 | -8,334 | -740,809 |
| TURTLE CAMERON | - | 88.89 | -15,000 | -1,333,350 |
| Jumlah Keseluruhan Kuantiti Bersih | -30,834 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,740,834 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 88.89 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TURTLE CAMERON | Pegawai | 01 Jul 2026 | Jual automatik (-) | 15,000 | 88.89 | 1,333,350 |
| SLOAN SHELDON | Pegawai | 01 Jul 2026 | Jual automatik (-) | 8,334 | 88.89 | 740,809 |
| SLOAN SHELDON | Pegawai | 01 Jul 2026 | Pelaksanaan pilihan | 8,334 | - | - |
| BURROWS SCOTT L | Pegawai | 01 Jul 2026 | Jual automatik (-) | 7,500 | 88.89 | 666,675 |
| BURROWS SCOTT L | Pegawai | 01 Jul 2026 | Pelaksanaan pilihan | 7,500 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |